Anti-dementia drugs and co-medication among patients with Alzheimer's disease: Investigating real-world drug use in clinical practice using the Swedish Dementia Quality Registry (SveDem)

Drugs and Aging

Volumn 31, Issue 3, 2014, Pages 215-224

  Fereshtehnejad, Seyed Mohammad ^a   Johnell, Kristina ^b   Eriksdotter, Maria ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINESTERASE INHIBITOR; HYPNOTIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PSYCHOTROPIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DEMENTIA; DRUG USE; FEMALE; HUMAN; ICD-10; INAPPROPRIATE DRUG USE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; POLYPHARMACY; PRIORITY JOURNAL; SWEDEN; AGED; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; REGISTER; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; POLYPHARMACY; PSYCHOTROPIC DRUGS; RECEPTORS, N-METHYL-D-ASPARTATE; REGISTRIES; SWEDEN;

EID: 84903372404     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-014-0154-8     Document Type: Article

References (43)

1. Henderson AS, Jorm A. Definition and epidemiology of dementia: a review. In: Maj M, Sartorius N, editors. Dementia. Chichester: Wiley; 2000.
2. Muayqil T, Camicioli R. Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias. Dement Geriatr Cogn Dis Extra. 2012;2(1):546-72.
3. National Institute for Health and Clinical Excellence (Great Britain); Social Care Institute for Excellence (Great Britain); National Collaborating Centre for Mental Health (Great Britain). Dementia: supporting people with dementia and their carers in health and social care. NICE clinical guideline 42. London: National Institute for Health and Clinical Excellence; 2006.
4. The Swedish National Board of Health and Welfare. National guidelines for treatment and care in dementia, 2010.
5. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):CD005593.
6. Rainer M, Wuschitz A, Jagsch C, Erb C, Chirikdjian JJ, Mucke HA. Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study. J Neural Transm. 2011;118(8):1255-9.
7. Jain KK. Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs. 2000;9(6):1397-406. (Pubitemid 30342623)
8. Defilippi JL, Crismon ML. Drug interactions with cholinesterase inhibitors. Drugs Aging. 2003;20(6):437-44. (Pubitemid 36629708)
9. Johnell K, Fastbom J, Rosen M, Leimanis A. Inappropriate drug use in the elderly: a nationwide register-based study. Ann Pharmacother. 2007;41(7):1243-8. (Pubitemid 47122563)
10. Montastruc F, Gardette V, Cantet C, Piau A, Lapeyre-Mestre M, Vellas B, et al. Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs! Eur J Clin Pharmacol. 2013;69(8):1589-97.
11. Epstein NU, Saykin AJ, Risacher SL, Gao S, Farlow MR. Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristics. Drugs Aging. 2010;27(8):677-86.
12. Haasum Y, Fastbom J, Johnell K. Institutionalization as a risk factor for inappropriate drug use in the elderly: a Swedish nationwide register-based study. Ann Pharmacother. 2012;46(3):339-46.
13. Religa D, Spangberg K, Wimo A, Edlund AK, Winblad B, Eriksdotter-Jonhagen M. Dementia diagnosis differs in men and women and depends on age and dementia severity: data from SveDem, the Swedish Dementia Quality Registry. Dement Geriatr Cogn Disord. 2012;33(2-3):90-5.
14. Wimo A, Religa D, Spångberg K, Edlund AK, Winblad B, Eriksdotter M. Costs of diagnosing dementia in Sweden: results from SveDem, the Swedish Dementia Registry. Int J Geriatr Psychiatry. 2013;28(10):1039-44.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.
16. World Health Organization. International statistical classification of diseases and related health problems, 10th ed. (ICD-10). Geneva: World Health Organization; 2009.
17. Johnell K, Religa D, Eriksdotter M. Differences in drug therapy between dementia disorders in the Swedish Dementia Registry: a nationwide study of over 7,000 patients. Dement Geriatr Cogn Disord. 2013;35(5-6):239-48.
18. Johnell K, Fastbom J. Antiepileptic drug use in community-dwelling and institutionalized elderly: a nationwide study of over 1,300,000 older people. Eur J Clin Pharmacol. 2011;67(10):1069-75.
19. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, McLachlan AJ, Cumming RG, Handelsman DJ, Le Couteur DG. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989-95.
20. Skoldunger A, Wimo A, Johnell K. Net costs of dementia in Sweden: an incidence based 10 year simulation study. Int J Geriatr Psychiatry. 2012;27(11):1112-7.
21. Jones RW. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry. 2010;25(6):547-53.
22. Maxwell CJ, Vu M, Hogan DB, Patten SB, Jantzi M, Kergoat MJ, Jette N, Bronskill SE, Heckman G, Hirdes JP. Patterns and determinants of dementia pharmacotherapy in a population-based cohort of home care clients. Drugs Aging. 2013;30(7):569-85.
23. The Swedish Medical Products Agency. Treatment of behavioral and psychological symptoms of dementia (BPSD). Vol. 5; The Swedish Medical Products Agency; 2008.
24. Holm L. Health care report 2009. Stockholm: National Board of Health and Welfare; 2010.
25. Johnell K, Fastbom J. Comparison of prescription drug use between community-dwelling and institutionalized elderly in Sweden. Drugs Aging. 2012;29(9):751-8.
26. Lau DT, Mercaldo ND, Shega JW, Rademaker A, Weintraub S. Functional decline associated with polypharmacy and potentially inappropriate medications in community-dwelling older adults with dementia. Am J Alzheimers Dis Other Demen. 2011;26(8):606-15.
27. Haider SI, Johnell K, Weitoft GR, Thorslund M, Fastbom J. The influence of educational level on polypharmacy and inappropriate drug use: a register-based study of more than 600,000 older people. J Am Geriatr Soc. 2009;57(1):62-9.
28. Wastesson JW, Parker MG, Fastbom J, Thorslund M, Johnell K. Drug use in centenarians compared with nonagenarians and octogenarians in Sweden: a nationwide register-based study. Age Ageing. 2012;41(2):218-24.
29. Bentue-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs. 2003;17(13):947-63. (Pubitemid 37410069)
30. Johnell K, Fastbom J. Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients. Drugs Aging. 2008;25(10):871-7.
31. Weiser M, Rotmensch HH, Korczyn AD, Hartman R, Cicin-Sain A, Anand R. A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. Int J Geriatr Psychiatry. 2002;17(4):343-6. (Pubitemid 34467093)
32. Rochon PA, Normand SL, Gomes T, Gill SS, Anderson GM, Melo M, Sykora K, Lipscombe L, Bell CM, Gurwitz JH. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168(10):1090-6. (Pubitemid 351749226)
33. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-43. (Pubitemid 41464695)
34. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57(4):613-20. (Pubitemid 32782987)
35. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54(12):2261-8. (Pubitemid 30416276)
36. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr. 2009;21(5):813-24.
37. Freund-Levi Y, Jedenius E, Tysen-Bäckström A-C, Lärksäter M, Wahlund LO, Eriksdotter M. Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia, an open randomized trial. Am J Geriatr Psychiatry. Epub 10 Sep 2013
38. Vida S, Des Rosiers P, Carrier L, Gauthier S. Prevalence of depression in Alzheimer's disease and validity of research diagnostic criteria. J Geriatr Psychiatry Neurol. 1994;7(4):238-44. (Pubitemid 24330516)
39. Tifratene K, Duff FL, Pradier C, Quetel J, Lafay P, Schuck S, Benzenine E, Quantin C, Robert P. Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer). Pharmacoepidemiol Drug Saf. 2012;21(9):1005-12.
40. Rosenberg PB, Mielke MM, Tschanz J, Cook L, Corcoran C, Hayden KM, Norton M, Rabins PV, Green RC, Welsh-Bohmer KA, et al. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry. 2008;16(11):883-92.
41. Nordström P, Religa D, Wimo A, Winblad B, Eriksdotter M. The use of cholinesterase inhibitors and the risk of myocardial infarction: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J. 2013;34(33):2585-91.
42. Reynish E, Cortes F, Andrieu S, Cantet C, Olde Rikkert M, Melis R, et al. The ICTUS Study: a prospective longitudinal observational study of 1,380 AD patients in Europe. Study design and baseline characteristics of the cohort. Neuroepidemiology. 2007;29(1-2):29-38. (Pubitemid 350191415)
43. Sonde L, Johnell K. Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres. PLoS One. 2013; 8(2):e57161.